Coronary artery disease (CAD) is one of the leading causes of death globally, and
antiplatelet therapy is crucial for both its prevention and treatment. Antiplatelet drugs such as …

BACKGROUND: Short-term (≤ 6 months) dual antiplatelet therapy (DAPT) and DAPT de-
escalation become attractive for patients with acute coronary syndrome. METHODS: A …

1University of Pisa and University Cardiology Division, Pisa University Hospital, Pisa, Italy;
and 2Fondazione VillaSerena per la Ricerca, Città Sant'Angelo, Pescara, Italy How to best …

Aim: To understand how attitudes toward pharmacogenomic (PGx) testing among
healthcare providers varies by specialty. Methods: Providers reported comfort ordering PGx …

Dual antiplatelet therapy with a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and
aspirin remains the standard of care for all patients undergoing percutaneous coronary …

Dual antiplatelet therapy (DAPT) is the gold standard after acute coronary syndromes (ACS)
or chronic coronary syndromes (CCS) undergoing percutaneous coronary intervention …

The traditional approach to management of cardiovascular disease relies on grouping
clinical presentations with common signs and symptoms into pre-specified disease …

CYP2C19 genotyping to guide antiplatelet therapy after patients develop acute coronary
syndromes (ACS) or require percutaneous coronary interventions (PCIs) reduces the …

Background The long-term prognostic implication of platelet reactivity after percutaneous
coronary intervention (PCI) is not clearly known. Objectives The impacts of platelet reactivity …

Percutaneous coronary intervention (PCI) is considered a relatively safe procedure
associated with low rates of complications, but is inevitably associated with short and mid-to …